M P Advisors

MP Group: Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment

It is our pleasure to share with you our latest report on Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment. The report provides market and competitive analysis of evolving therapeutic landscape of IBD while anticipating how the future treatment paradigm is likely to evolve. Key Highlights of the Deck - Assessment of the evolving treatment paradigm: Explore the market trends and transition from conventional step-up approaches to a more aggressive top-down strategy Current landscape of targeted therapies: Insights into the…

Continue Reading

MP Group: Outlook on Growth of the US biosimilars market – Key trends and opportunities

Pleasure to share our Outlook on Growth of the US biosimilars market – Key trends and opportunities. Historically, the US biosimilars market has posed several challenges restricting its penetration. Ambiguous regulatory guidelines contributing to high cost and timelines for development, patent dance causing uncertainties with launch timelines and barriers posed by the innovators limiting the market penetration – all of these led to the biosimilars market only dominated by the innovator companies. However, over the last 3-5 years, the landscape…

Continue Reading
Close Menu